Filing Flows › Sutro Biopharma (STRO) › Recalls, complaints & regulation
Sutro Biopharma (STRO): clinical trials
Sutro Biopharma (STRO) beyond its filings: 2 active clinical trials.
Sutro Biopharma's latest quarter
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Sutro Biopharma have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.